Your session is about to expire
← Back to Search
Device
Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease
N/A
Waitlist Available
Led By Azim S Gangji, MD
Research Sponsored by Mespere Lifesciences Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-3 hours
Awards & highlights
No Placebo-Only Group
Summary
The primary objective of this study is to determine whether a correlation exists between the Mespere Non-Invasive Central Venous Pressure (NICVP) device for measuring central venous pressure (CVP), and assessment of CVP via physical examination.
Eligible Conditions
- Central Venous Pressure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-3 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-3 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Central Venous Pressure (CVP)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Healthy subjectsExperimental Treatment2 Interventions
minimum 3 subjects (male and female)
Group II: Chronic Kidney DiseaseExperimental Treatment2 Interventions
minimum 7 subjects (male and female)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Physical examination of jugular vein
2012
N/A
~50
Find a Location
Who is running the clinical trial?
St. Joseph's Healthcare HamiltonOTHER
202 Previous Clinical Trials
26,925 Total Patients Enrolled
Mespere Lifesciences Inc.Lead Sponsor
10 Previous Clinical Trials
542 Total Patients Enrolled
Melissa T Perri, MEScStudy DirectorMespere Lifesciences Inc.
Azim S Gangji, MDPrincipal InvestigatorSt. Joseph's Healthcare Hamilton
1 Previous Clinical Trials
22 Total Patients Enrolled